Medical Excellence Capital — Full Portfolio
21 tracked investments · listed companies and verified rows first
ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS).
BiotechDeep TechMedical DevicesNissequogue, US
Valerie Estess(Director)
BoardJohn Prufeta(Director)inJoni Mancini(Executive Officer)inBrent R. Stockwell(Chair of the Department of Biological Science, Professor at Columbia University)Hynek Wichterle(Jerry and Emily Spiegel Professor at Columbia University)
Board seatEric Heil· per SEC Form D
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins, along with computational design tools for targeted drug discovery.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)inEric Heil(Chief Executive Officer)in
Co-investorsSmartGateVC
Pleno develops a genomic testing instrument platform designed to make multiomics testing faster, lower-cost, and higher-plex than existing methods like NGS, PCR, and microarrays.
BiotechHardwareHealthtech
Co-investorsForesite CapitalDeerfield Management Company
Ladder Bio (formerly ThirdLaw Molecular) develops Spiroligomer molecules, a class of synthetic, modular fused-ring compounds designed for highly selective binding to target proteins.
BiotechDeep TechMedical DevicesBlue Bell, US
Christian Schafmeister(Founder)Eric Heil(Chief Executive Officer)in
Co-investorsSmartGateVC
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inDamien McDevitt(President and Chief Executive Officer)in
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+4 more
Avilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process.
BiotechWaltham, US
THERESA CAMERON(Director)MARTIN FREED(Director)inSTEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)
Co-investorsAstellas Venture Management LLCRA CapitalSanofi VenturesOpenSky Ventures
ClicBio develops oral small-molecule CLIC1 inhibitors to treat metabolic diseases by modulating appetite through hypothalamic neuron regulation.
BiotechDeep TechHealthtech
John Dobak(CEO and Co-Founder)Jay Hagan(Board Member and Co-Founder)Bruce Steel(Board Member and Co-Founder)Olivia Osborn(Co-Founder/Advisor)
GCTx develops an induced pluripotent stem cell (iPSC) programming platform called TFome™ that uses synthetic biology, gene editing, and machine learning to improve cell therapy development and scaling.
AI & Machine LearningBiotechMedical DevicesCambridge, US
George Church(Co-Founder & Scientific Advisor)Parastoo Khoshakhlagh(Chief Executive Officer & Co-Founder)inAlex Ng(Chief Innovation Officer & Co-Founder)in
Co-investorsAndreessen HorowitzGlobal BrainHumboldt
Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.
BiotechDigital HealthMedical DevicesWaltham, US
Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)
BoardLaura Brass(Director)inKai Wucherpfennig(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundNovartis Venture FundOno Venture Investment, Inc.Solasta Ventures+3 more
Nobias Therapeutics is a clinical-stage drug developer creating small-molecule therapeutics for genetically-defined rare diseases, initially focused on pediatric indications with potential expansion into adult and non-rare conditions.
AI & Machine LearningBiotechHealthtech
Hakon Hakonarson(Co-Founder and Chief Scientific Advisor)Brian Halak(Co-Founder)inPatrick Dougherty(Chief Executive Officer)Ryan McMillian(Consulting Chief Financial Officer)
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerFoothill VenturesIllumina VenturesVivo CapitalARCH Venture Partners+1 more
San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
Co-investorsARCH Venture PartnersLightstone Ventures
Truvian builds an on-site blood diagnostics platform that combines clinical chemistry, immunoassay, and hematology testing in a single compact instrument.
BiotechDigital HealthMedical DevicesSan Diego, US
Dena Marrinucci(Co-Founder & Chief Operating Officer)inMichael J. Mina(Chief Medical and Strategy Officer)in
Co-investorsDns CapitalGreatPoint VenturesWittington VenturesDomain AssociatesXB VenturesOS Fund
TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform.
BiotechHealthtechSan Carlos, US
Caitlyn Miller(CEO & Co-Founder)inJennifer Cochran(Co-Founder)Carolyn Bertozzi(Co-Founder)Ronald Levy(Co-Founder)
BoardOmri Amirav-Drory(Director)inJohn Prufeta(Director)in
Co-investors2048 VenturesFifty YearsNFX
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rejuvitas, Inc.ClicBioImmunitasLadder BioLadder Bio (formerly ThirdLaw Molecular)Nobias TherapeuticsThirdLaw Molecular
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.